Next Article in Journal
Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development
Previous Article in Journal
The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation
Open AccessArticle

A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate

1
Biotechnology and Biopharmaceutical Laboratory, Departamento de Fisiopatología; Facultad de Ciencias Biológicas, Universidad de Concepción, Víctor Lamas 1290, P.O. Box 160-C, Concepción 4079386, Chile
2
Molecular Virology and Pathogen Control Laboratory, Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile (USACH), Alameda 3363, Correo 40, Casilla 33, Santiago 9170022, Chile
3
Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile (USACH), Alameda 3363, Correo 40, Casilla 33, Santiago 9170022, Chile
4
Natural History Museum of Potsdam, 14467 Potsdam, Germany
5
Laboratorio of Cultivos Celulares, Escuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Ave. Brasil 2085, Valparaíso 2362803, Chile
6
Moderna Therapeutics 100 Upland Rd., Norwood, MA 02062, USA
7
Pathology and Preventive Medicine Department, School of Veterinary Sciences, Universidad de Concepción, Ave. Vicente Méndez 595, Chillan 3812120, Chile
*
Authors to whom correspondence should be addressed.
Viruses 2020, 12(4), 385; https://doi.org/10.3390/v12040385
Received: 14 January 2020 / Revised: 9 March 2020 / Accepted: 15 March 2020 / Published: 31 March 2020
(This article belongs to the Section Antivirals & Vaccines)
Recombinant vaccines have low-cost manufacturing, regulatory requirements, and reduced side effects compared to attenuated or inactivated vaccines. In the porcine industry, post-weaning multisystemic disease syndrome generates economic losses, characterized by progressive weight loss and weakness in piglets, and it is caused by porcine circovirus type 2 (PCV2). We designed a chimeric antigen (Qm1) to assemble the main exposed epitopes of the Cap-PCV2 protein on the capsid protein of the tobacco necrosis virus (TNV). This design was based on the Cap-N-terminal of an isolated PCV2 virus obtained in Chile. The virus was characterized, and the sequence was clustered within the PCV2 genotype b clade. This chimeric protein was expressed as inclusion bodies in both monomeric and multimeric forms, suggesting a high-molecular-weight aggregate formation. Pigs immunized with Qm1 elicited a strong and specific antibody response, which reduced the viral loads after the PCV2 challenge. In conclusion, the implemented design allowed for the generation of an effective vaccine candidate. Our proposal could be used to express the domains or fragments of antigenic proteins, whose structural complexity does not allow for low-cost production in Escherichia coli. Hence, other antigen domains could be integrated into the TNV backbone for suitable antigenicity and immunogenicity. This work represents new biotechnological strategies, with a reduction in the costs associated with vaccine development. View Full-Text
Keywords: PCV2 virus; recombinant antigens production; vaccines; biotechnology strategies PCV2 virus; recombinant antigens production; vaccines; biotechnology strategies
Show Figures

Figure 1

MDPI and ACS Style

Lamazares, E.; Gutiérrez, F.; Hidalgo, A.; Gutiérrez, N.A.; Espinoza, F.I.; Sánchez, O.; Cortez-San Martín, M.; Mascayano, C.; González, J.; Saavedra, J.; Altamirano, C.; Mansur, M.; Ruiz, Á.; Toledo, J.R. A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate. Viruses 2020, 12, 385.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop